Why your peptides might not be working: 8 common reasons

Guide 8 min read Reviewed

If you're not seeing results from your peptide protocol, the issue is usually one of these eight factors, from sourcing and storage to dosing, timing, and unrealistic expectations.

Contents5
  1. 1The expectation problem
  2. 2The 8 most common reasons
  3. 3A diagnostic framework
  4. 4Frequently asked questions
  5. 5References

The expectation problem

A frequent reason a protocol seems not to be working is a mismatch between what was expected and what the compound can deliver in the time given.

For most research peptides, the human evidence is thin. In a 2025 systematic review of BPC-157, 35 of the 36 included studies were preclinical and 1 was clinical, and the FDA says it has not identified any human exposure data for TB-500.21 Many of the effects described online have no human trial behind them, so there is no published timeline to measure against.

Short before-and-after videos compress weeks or months of a protocol into a scroll. The endpoint is visible; the timeline is not. A week into a long-acting compound, levels are still building toward steady state.

Where trials exist, they run for months. In STEP 1, semaglutide 2.4 mg once weekly gave a mean body weight change of -14.9% at week 68, against -2.4% with placebo; in SURMOUNT-1, tirzepatide gave -15.0% to -20.9% at week 72, against -3.1%.1011

The pharmacokinetic reality

Levels build over several half-lives of consistent dosing to reach steady-state, the point at which the amount entering equals the amount being cleared. A compound with a 2-hour half-life dosed daily is close to steady state within a day or two. Semaglutide, with a half-life of approximately 1 week, reaches steady state after 4 to 5 weeks of weekly doses, by its label.3 Biological effects can lag behind levels. See the guide to saturation and steady state for more.

The 8 most common reasons

When a peptide protocol is not producing the expected results, these eight factors are the places to look. No study ranks how often each is the cause, so the order here is the order of checking, from the vial outward.

1

Product quality

Products range from approved, manufactured medicines to research-labelled powders. The FDA has warned companies selling semaglutide, tirzepatide and retatrutide falsely labelled "for research purposes" or "not for human consumption", and says such products are of unknown quality; it also describes counterfeit products that contain the wrong ingredient, too little, too much or none.4 A compound that is degraded, underdosed, or not the labelled peptide at all will not produce the expected effects however well everything else is done.

Analytical testing is how identity and purity are checked. Reversed-phase high-performance liquid chromatography (HPLC) and high-resolution mass spectrometry are among the techniques used in the pharmaceutical industry to characterise peptides and their impurities and degradation products.5 Some sellers publish batch-specific certificates of analysis (COAs) from outside laboratories.

Community forums keep informal vendor reputations, which carry their own biases. A COA reports what one lab found in one batch.

On product sourcing

This article discusses product quality as one factor in protocol outcomes. Milligram does not endorse, recommend, or review specific vendors or sources. Product sourcing decisions carry inherent variability that is outside the scope of a tracking and analytics tool.

2

Improper storage

A peptide can arrive intact and degrade before the vial is finished because of storage. The FDA says injectable GLP-1 drugs require refrigeration as in their package inserts, and recommends not using one that arrives warm, as this can affect the drug.4 A review of synthetic peptide medicines covers degradation products and aggregation as what quality testing looks for.5

Light, damaged seals, and mixing with plain sterile water are other storage problems. Sterile water for injection has no bacteriostat and is single-dose only, while bacteriostatic water contains benzyl alcohol as a preservative and is made for repeated withdrawals.76 For more, see the peptide storage guide.

The pattern on approved labels is cold and dark: Humatrope's reconstituted cartridges are refrigerated at 2-8°C, kept in the carton to protect from light, and used within 28 days.9 For multiple-dose vials of compounded GLP-1 medicines, the FDA recommends discarding the vial within 28 days after first use, because of an increased risk of contamination.4

3

Incorrect reconstitution

Reconstitution errors change the concentration of the solution, so every dose drawn from that vial is off by the same proportion. Two common mistakes are adding the wrong volume of BAC water and mixing too hard.

If a vial contains 5mg of peptide and the target dose is 250mcg, the reconstitution volume determines how many units on the syringe equal 250mcg. Add 2mL and each 10 units equals 250mcg. Add 1mL and each 10 units equals 500mcg, double the intended dose. Add 3mL and each 10 units equals approximately 167mcg, a third less than intended. The math error cascades through every dose for the life of that vial.

Approved labels for powdered peptide medicines say not to shake. The Serostim label aims the stream of diluent against the glass vial wall to prevent foaming and swirls with a gentle rotary motion until dissolved.8 The reconstitution calculator takes the arithmetic out of this step.

4

Underdosing

Underdosing can follow from reconstitution errors (Reason 3) or happen on its own, if the math is right but the dose is below what produces an effect.

Where trials exist, they show dose matters: in SURMOUNT-1, mean weight change at 72 weeks was -15.0% at 5 mg of tirzepatide and -20.9% at 15 mg.11 For research peptides with no human dose trial, there is no published effective dose to compare against.1

The reconstitution calculator checks that the volume drawn on the syringe matches the dose in micrograms or milligrams. The FDA has received reports of adverse events, some needing hospital care, that may be related to people measuring and self-administering incorrect doses of compounded semaglutide.4

5

Inconsistent dosing

Consistent doses at regular intervals build and hold steady-state levels. Skipped days, large shifts in timing, or breaks keep steady state from being reached or held.

For a compound with a short half-life, a missed daily dose lets levels fall close to zero before the next one; BPC-157's half-life was under 30 minutes in animal studies.18 For a compound with a long half-life, like semaglutide at approximately 1 week, the buffer is much larger, but missed doses over weeks still slow the climb to steady state.3

Each missed dose creates a dip and a rebuild, so the time spent at steady state shrinks by more than the share of doses missed.

6

Not enough time

Different compounds work on different timescales. A protocol that shows results at 12 weeks may show nothing at 3 weeks.

The table below sets out what the published evidence says about timing for each category. Where no human timeline was found, it says so.

Compound category Published timeline What the evidence is
Healing peptides (BPC-157, TB-500) None found Mostly preclinical; no human exposure data for TB-50021
GH-releasing (CJC-1295, Ipamorelin, MK-677) IGF-I up 9-11 days per dose CJC-1295 trial in healthy adults; an ibutamoren (MK-677) hip fracture trial stopped early for a heart failure signal121
GLP-1 agonists (Semaglutide, Tirzepatide) 68-72 weeks in phase 3 Mean weight change -14.9% (semaglutide) and -15.0% to -20.9% (tirzepatide)1011
Skin / collagen (GHK-Cu) None found for injection Animal and cosmetic product studies; limited human safety data131
Cognitive (Semax, Selank) None found FDA lists no, or limited, human safety information1
Tanning (Melanotan II) None found Case reports of serious adverse events, including melanoma1

No published minimum evaluation period exists for research peptides. For testosterone, a review of replacement studies found changes in fat mass, lean body mass and muscle strength within 12 to 16 weeks, which gives a sense of how long body composition changes take.17

7

No tracking system

Gradual changes are hard to see without data. When changes happen a little at a time over weeks, the person living them often cannot perceive them; each day looks and feels much like the day before.

A month of daily check-in data (energy, sleep quality, recovery, body weight) can show a trend that daily life hides: an energy rating that averaged 2.5 out of 5 in week one and 3.8 in week four, for example.

Daily subjective check-ins, even simple 1-5 scales on a few markers, are not scientifically rigorous, but they make slow trends visible and answer "is it working?" with a record instead of a feeling.

8

Lifestyle factors

A compound works within the body's other inputs. Ipamorelin, for example, releases growth hormone through a GHRP-like receptor; what that GH does downstream also depends on protein intake, training, sleep and stress.20

Likewise, tissue that is repeatedly re-injured, by training through an injury unchanged, keeps adding damage whatever else is in the protocol.

For protein, a meta-analysis of 49 trials found protein supplementation added to resistance training gains in fat-free mass, with no further gain beyond a total intake of about 1.62 g/kg/day.16 No trial of GH-releasing peptides combined with these inputs was found.

Lifestyle factors that bear on the same systems:

  • Insufficient sleep: growth hormone is released during slow wave sleep, while cortisol is inhibited.14
  • Low protein intake: protein supplementation increased fat-free mass gains during resistance training, up to about 1.62 g/kg/day of total protein.16
  • No training stimulus: the protein meta-analysis measured gains during resistance training of 6 weeks or more; the training was the stimulus.16
  • Chronic stress and elevated cortisol: cortisol is the stress hormone that slow wave sleep inhibits while GH is released.14
  • Alcohol: in five healthy young men, alcohol at 0.8 g/kg suppressed night-time plasma GH by 70-75% on both the first and the ninth night.15

A diagnostic framework

When a protocol does not appear to be producing results, a systematic order rules out variables faster than guessing. The sequence below moves from the vial outward:

  1. Verify product source and quality. Is there a batch-specific COA from an outside lab? What does it show?
  2. Check storage conditions. Has the reconstituted vial been refrigerated consistently? How old is it? Has it been exposed to heat or light? Was it reconstituted with bacteriostatic water?
  3. Verify reconstitution math. A reconstitution calculator confirms the BAC water volume, resulting concentration, and units to draw for the target dose.
  4. Confirm dosing consistency. How many doses have been missed in the current protocol? What percentage of expected doses have been taken? Is the dosing interval consistent?
  5. Assess the timeline. How many days or weeks into the protocol? Has enough time elapsed for the compound's mechanism to produce observable effects? (See the timeline table above.)
  6. Review lifestyle inputs. Sleep duration and quality, protein intake, training consistency, stress levels, alcohol consumption. Are the conditions present for the peptide's mechanism to produce downstream effects?
  7. Consider objective measurement. Bloodwork can show measurable activity regardless of how things feel: IGF-1 for GH-releasing peptides, which a review describes as a stable indication of integrated GH secretion; HbA1c and fasting glucose for GLP-1 agonists; inflammatory markers for healing peptides.19
  8. Evaluate the compound itself. With everything above ruled out, the compound may not be producing a response at this dose in this person. Any change of dose or compound is a decision for the person and their clinician.
The tracking advantage

Most of these steps are easier with data. A dose log answers step 4. Daily check-in trends answer "is it working?" with a record instead of memory. Protocol start dates answer step 5. See the guide on knowing if your peptides are working for more.

Frequently asked questions

How can I verify the quality of my peptides?

HPLC (high-performance liquid chromatography) and mass spectrometry are the standard techniques for characterising peptide identity, impurities and degradation products.5 Some sellers publish batch-specific certificates of analysis (COAs) from outside laboratories. For GLP-1 products sold as research chemicals, the FDA says they are of unknown quality.4

Can peptides lose potency over time?

Yes. A review of synthetic peptide medicines covers peptide degradation, degradation products and aggregation.5 Approved labels set limits: Humatrope's reconstituted cartridges are stable for up to 28 days refrigerated at 2-8°C, with no more than 30 minutes a day at room temperature, and the FDA recommends discarding multiple-dose vials of compounded GLP-1 medicines within 28 days after first use.94

How do I know if my peptide dose is correct?

A reconstitution calculator confirms the concentration (mcg per unit on the syringe) before the first draw from a new vial. The volume of BAC water added sets the concentration, and the concentration sets what each unit on the syringe delivers. The FDA has received adverse event reports that may be related to people measuring incorrect doses of compounded semaglutide.4

What is the minimum effective duration for a peptide protocol?

It varies by compound. The GLP-1 phase 3 trials ran 68 and 72 weeks; semaglutide's mean weight change at week 68 was -14.9%.1011 For testosterone, body composition changes appeared within 12 to 16 weeks in a review of replacement studies.17 For research peptides such as BPC-157, no human timeline was found.2

When is it appropriate to switch compounds or adjust a protocol?

The checks above come first: product quality, reconstitution math, storage, dosing consistency, and time elapsed. Bloodwork (IGF-1 for GH peptides, HbA1c for GLP-1 agonists) gives an objective read on whether the compound is biologically active.19 Any change of dose or compound is a decision for the person and their clinician.

References

  1. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). 2026. fda.gov
  2. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov
  3. Novo Nordisk (DailyMed). Ozempic (semaglutide) injection label. 2026. dailymed.nlm.nih.gov
  4. US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 1 October 2026). 2026. fda.gov
  5. Sharma N et al. Synthetic pharmaceutical peptides characterization by chromatography principles and method development. J Sep Sci. 2022. pubmed.ncbi.nlm.nih.gov
  6. Henry Schein (DailyMed). Bacteriostatic Water for Injection, USP, multiple-dose vial label. 2026. dailymed.nlm.nih.gov
  7. Henry Schein (DailyMed). Sterile Water for Injection, USP, single-dose vial label. 2026. dailymed.nlm.nih.gov
  8. EMD Serono (DailyMed). Serostim (somatropin) label. 2026. dailymed.nlm.nih.gov
  9. Eli Lilly (DailyMed). Humatrope (somatropin) label. 2026. dailymed.nlm.nih.gov
  10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov
  11. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov
  12. Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov
  13. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. pubmed.ncbi.nlm.nih.gov
  14. Van Cauter E et al. Metabolic consequences of sleep and sleep loss. Sleep Med. 2008. pubmed.ncbi.nlm.nih.gov
  15. Prinz PN et al. Effect of alcohol on sleep and nighttime plasma growth hormone and cortisol concentrations. J Clin Endocrinol Metab. 1980. pubmed.ncbi.nlm.nih.gov
  16. Morton RW et al. Protein supplementation and resistance training-induced gains in muscle mass and strength: a systematic review, meta-analysis and meta-regression. Br J Sports Med. 2018. pubmed.ncbi.nlm.nih.gov
  17. Saad F et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011. pubmed.ncbi.nlm.nih.gov
  18. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022. pubmed.ncbi.nlm.nih.gov
  19. Cardoso LM et al. Acromegaly: biochemical diagnosis. Vitam Horm. 2026. pubmed.ncbi.nlm.nih.gov
  20. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov